Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Jul 1;74(3):732-9.
doi: 10.1016/j.ijrobp.2008.08.058. Epub 2008 Dec 25.

Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas

Thomas F DeLaney  1 , Norbert J Liebsch, Francis X Pedlow, Judith Adams, Susan Dean, Beow Y Yeap, Patricia McManus, Andrew E Rosenberg, G Petur Nielsen, David C Harmon, Ira J Spiro, Kevin A Raskin, Herman D Suit, Sam S Yoon, Francis J Hornicek
Affiliations
Clinical Trial

Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas

Thomas F DeLaney et al. Int J Radiat Oncol Biol Phys. .

Abstract

Purpose: Radiotherapy (XRT) for spine sarcomas is constrained by spinal cord, nerve, and viscera tolerance. Negative surgical margins are uncommon; hence, doses of >or=66 Gy are recommended. A Phase II clinical trial evaluated high-dose photon/proton XRT for spine sarcomas.

Methods and materials: Eligible patients had nonmetastatic, thoracic, lumbar, and/or sacral spine/paraspinal sarcomas. Treatment included pre- and/or postoperative photon/proton XRT with or without radical resection; patients with osteosarcoma and Ewing's sarcoma received chemotherapy. Shrinking fields delivered 50.4 cobalt Gray equivalent (Gy RBE) to subclinical disease, 70.2 Gy RBE to microscopic disease in the tumor bed, and 77.4 Gy RBE to gross disease at 1.8 Gy RBE qd. Doses were reduced for radiosensitive histologies, concurrent chemoradiation, or when diabetes or autoimmune disease present. Spinal cord dose was limited to 63/54 Gy RBE to surface/center. Intraoperative boost doses of 7.5 to 10 Gy could be given by dural plaque.

Results: A total of 50 patients (29 chordoma, 14 chondrosarcoma, 7 other) underwent gross total (n = 25) or subtotal (n = 12) resection or biopsy (n = 13). With 48 month median follow-up, 5-year actuarial local control, recurrence-free survival, and overall survival are: 78%, 63%, and 87% respectively. Two of 36 (5.6%) patients treated for primary versus 7/14 (50%) for recurrent tumor developed local recurrence (p < 0.001). Five patients developed late radiation-associated complications; no myelopathy developed but three sacral neuropathies appeared after 77.12 to 77.4 Gy RBE.

Conclusions: Local control with this treatment is high in patients radiated at the time of primary presentation. Spinal cord dose constraints appear to be safe. Sacral nerves receiving 77.12-77.4 Gy RBE are at risk for late toxicity.

PubMed Disclaimer

Figures

1
1
Actuarial local control in the 50 patients treated in the study.
2
2
Progression-free survival in the study patients.
3
3
Overall survival in the patients in the study.
See this image and copyright information in PMC

References

    1. Schultheiss TE, Kun LE, Ang KK, et al. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys. 1995;31:1093–1112. - PubMed
    1. Zagars GK, Ballo MT. Significance of dose in postoperative radiotherapy for soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2003;56:473–481. - PubMed
    1. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16:197–203. - PubMed
    1. Delaney TF, Kepka L, Goldberg SI, et al. Radiation therapy for control of soft-tissue sarcomas resected with positive margins. Int J Radiat Oncol Biol Phys. 2007;67:1460–1469. - PubMed
    1. Kepka L, DeLaney TF, Goldberg SI, et al. Results of radiation therapy for unresected soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2005;63:852–859. - PubMed

Publication types

MeSH terms